Cambiamento di rotta nel trattamento del tumore ovarico in Campania: il punto nell’incontro patrocinato a Napoli da ACTO Campania e sponsorizzato da GSK
(Adnkronos) - Dai controlli alla scoperta della malattia, dalle terapie sempre più di precisione, ai test genomici indispensabili per la personalizzazione della cura del tumore ovarico, patologia che interessa in Italia circa 5000 nuovi casi ogni anno, al centro dell’incontro “Tumore ovarico in Campania: Cambiamo Rotta” patrocinato a Napoli da ACTO Campania e sponsorizzato da GSK.
Category
🗞
NewsTranscript
00:00From alarm bells and checks to the discovery of the disease, from increasingly more precise therapies to the challenges of an early diagnosis of ovarian tumour,
00:13a pathology that interests in Italy about 5,000 new cases every year, and at the heart of the meeting, sponsored by Napoli d'Acto Campania and sponsored by GSK, from the title Cambiamo Ruta.
00:24Doctors, researchers, institutions and patients have come together on the latest progress in the research on this aneoplasy, exploring new frontiers in personalized therapy and in the multidisciplinary approach to disease management.
00:38In Campania we have developed two very important documents for some years, which are the PDTA of ovarian tumours, which defines the diagnostic and therapeutic aspects,
00:49and the PDTA of hereditary tumours, which is part of a comprehensive plan of the Campania region to identify the tumours transmitted on a hereditary basis.
00:59We have tried to apply both these two documents. For the part of therapy, for example, we have selected the surgical centres that are able to do this difficult surgery, which is the ovarian tumour surgery.
01:12For hereditary tumours we have identified six centres, one per million inhabitants, which are responsible for oncogenetic screening, that is, for the search for mutations and then for the prevention that follows.
01:27Today, thanks also to the work of sensitization carried out in full in all of Italy, 70% of women with ovarian tumour already know the disease before the diagnosis,
01:37but there is an aspect on which women are not yet aware, namely the importance of the structure in which it is cured, which can make the difference,
01:44an aspect that Campania sees among the best oncological networks in Italy, but much more needs to be done in terms of prevention.
01:51What IOM is trying to do is to improve the equity of the treatments on the national territory through the production of guidelines,
02:02which dictate standards that, we are confident of being able to say, are applied throughout the national territory,
02:11in addition to the diagnostic-therapeutic guidelines, and to push because the regional administrators, not only in Campania and in the regions of southern Italy, but everywhere,
02:25are committed much more to making the prevention programs efficient.
02:30Looking to the future, it is essential that the scientific community, researchers and political decision-makers work together to promote prevention,
02:38while the development of new targeted treatments and innovative therapies offers hope for a more efficient and personalized management of the disease.
02:46We have many innovations, fortunately, both in the surgical field, with the development of mini-invasive surgeries,
02:53laparoscopic and robotic, but also in the pharmacological field.
02:57For example, in particular, we have a new class of drugs called inhibitor PARP,
03:02which today we routinely use in clinical practice, but require molecular tests.
03:08Therefore, the quality of the treatments today for a center or for an oncological network, as in our case,
03:14means identifying those centers that are also able to perform molecular tests.
03:20Only surgery or only medical therapy is no longer enough.